Evidence map›Paper›PMID 29497579›Full record

ReviewInnovations in clinical neuroscience2018

Cognitive Impairment Associated with Cancer: A Brief Review.

J Cara Pendergrass, Steven D Targum, John E Harrison

3 registry-linked trialsOpen access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in Innovations in clinical neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 135 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 7 pooled it
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04673305 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Cognitive Status Assessment In Elderly Patients With Active Treatment For Haematological Malignancies

TypeinterventionalSponsorOspedale San Carlo BorromeoRan2021 to 2023Enrolled60ConditionsCognitive Impairment, Haematological Malignancy, Chemo-brainArmsCognitive Assessment, Cytokine dosage
NCT05409248 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Cognitive Stimulation Intervention Program for Cancer Survivors and Its Benefit on Cognitive Performance and Quality of Life

TypeinterventionalSponsorUniversidad Antonio de NebrijaRan2022 to 2023Enrolled120ConditionsBreast Cancer, Cognitive DeclineArmsPersonalized cognitive stimulation, Sham cognitive stimulation
NCT05819008 recruitingnot on this mapstarted 2023, after this paper: background citation

Remote Neuropsychological Assessment of Patients With Neurological Disorders and Injuries

TypeobservationalSponsorUmeå UniversityRan2023 to 2027Enrolled350ConditionsTraumatic Brain Injury, Stroke, Multiple Sclerosis, Parkinson DiseaseArmsNeuropsychological Assessment
3 · Its place in the literature

Who cites it

135 citing papers in PubMed, 7 syntheses or guidelines pooled it, 218 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Trial
  16. Efficacy of Acupuncture Therapy for Chemotherapy-Related Cognitive Impairment in Breast Cancer Patients.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Trial
  17. Article
  18. Methodology of analysis of cognitive impairment in longitudinal randomized clinical trials in oncology: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  19. Article
  20. Article

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

J Cara PendergrassDrs. Pendergrass and Targum are with Bracket Global and Clintara LLC, A Bracket Company, in Boston, Massachusetts.
Steven D TargumDrs. Pendergrass and Targum are with Bracket Global and Clintara LLC, A Bracket Company, in Boston, Massachusetts.
John E HarrisonDrs. Pendergrass and Targum are with Bracket Global and Clintara LLC, A Bracket Company, in Boston, Massachusetts.
Clinton Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This brief review explores the areas of cognitive impairment that have been observed in cancer patients and survivors, the cognitive assessment tools used, and the management of the observed cognitive changes. Cognitive changes and impairment observed in patients with cancer and those in remission can be related to the direct effects of cancer itself, nonspecific factors or comorbid conditions that are independent of the actual disease, and/or the treatments or combination of treatments administered. Attention, memory, and executive functioning are the most frequently identified cognitive domains impacted by cancer. However, the prevalence and extent of impairment remains largely unknown due to marked differences in methodology, definitions of cognitive impairment, and the assessment measures used. Assessment of cognitive functioning is an important and necessary part of a comprehensive oncological care plan. Research is needed to establish a better understanding of cognitive changes and impairments associated with cancer so that optimal patient outcomes can be achieved.

Indexed as

cancerchemotherapyCognitioncognitive impairmentneuropsychological assessmenttreatment

Identifiers

PMID29497579
PMCPMC5819720
OpenAlexW2920601105

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.